Every 10-Q that ProAssurance Corporation (PRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRA filings page.
ProAssurance Corporation reported first‑quarter 2026 net income of $8.5 million, reversing a $5.8 million loss a year earlier. Total revenues were $262.6 million, with net premiums earned of $223.5 million and net investment income of $40.0 million. Underwriting benefited from $4.9 million of net favorable prior‑year loss reserve development, while reserve for losses and loss adjustment expenses declined to $3.0 billion. Operating cash flow was negative $21.3 million, largely due to claim payments and changes in other liabilities. Shareholders’ equity slipped to $1.34 billion as unrealized investment losses drove a $17.9 million after‑tax decline in accumulated other comprehensive income.
The company is progressing toward its all‑cash merger with The Doctors Company at $25.00 per PRA share. Multiple insurance regulators, including Alabama, Texas and Vermont, along with Lloyd’s of London and the Cayman Islands Monetary Authority, have granted approvals. Reviews remain pending in California and Pennsylvania, and ProAssurance “continues to anticipate” closing by June 30 2026. The company incurred about $1.4 million of pre‑tax merger‑related costs in the quarter and expects total transaction expenses to be significant.
ProAssurance (PRA) reported third‑quarter results and updated its pending merger with The Doctors Company. Total revenues were $279,554 (in thousands) and net income was $1,446 (in thousands), for EPS of $0.03. Net premiums earned were $233,404 (in thousands) and net investment income was $40,442 (in thousands). Expenses totaled $275,185 (in thousands), driven by losses and loss adjustment expenses of $186,199 (in thousands) and operating expense of $46,817 (in thousands).
On the balance sheet, shareholders’ equity rose to $1,304,252 (in thousands), as accumulated other comprehensive loss improved to $(90,841) from $(172,391) at year‑end, while the reserve for losses and LAE decreased to $3,118,937 (in thousands). Year‑to‑date operating cash flow was $(12,476) (in thousands).
The company continues to pursue its all‑cash merger at $25.00 per share. Stockholders approved the deal; HSR early termination was granted, and regulatory approvals have been received in Alabama, the District of Columbia, Illinois, Missouri and Vermont, with reviews pending in California, Pennsylvania and Texas. Transaction costs were $3.0 million in Q3 and $14.6 million year‑to‑date. The company anticipates closing by June 30, 2026, subject to remaining conditions.
ProAssurance (PRA) Q2-25 10-Q highlights: Net premiums earned slipped 3% YoY to $232.4 m, but higher investment income (+6% to $38.9 m) and a 14% drop in loss costs lifted quarterly net income 41% to $21.9 m (diluted EPS $0.42). Six-month revenues fell 5% to $548.8 m and net income declined 20% to $16.1 m (EPS $0.31) after $11.6 m merger-related expenses.
Shareholders’ equity rose 6% since year-end to $1.28 bn as AOCI improved $55.8 m with bond-market recovery. Book value approximates $24–25 per share, near the $25 cash offer in the pending merger with The Doctors Company. The deal, signed 19 Mar 25, gained shareholder approval 24 Jun 25 and early HSR clearance 2 Jul 25; closing targeted 1H-26, pending remaining regulatory consents.
- Combined ratio (est.) improved to ~96.4% from ~98.2%.
- Operating cash flow YTD: –$39.7 m (–$24.5 m PY).
- Investment portfolio $4.38 bn; unrealized loss narrowed to $116.6 m.
- Debt $422.6 m; net leverage ~0.3× equity.
- Sale of Franklin, TN property generated $19.3 m cash and $2.2 m gain.
No new accounting standards adopted; upcoming FASB disclosure rules being evaluated.